Unmasking the cryptic immunopeptidome of EZH2 mutated diffuse large B-cell lymphomas through combination drug treatment
C. M. Bourne, S. S. Mun, T. Dao, Z. E. H. Aretz, R. S. Gejman, A. Daman, K. Takata, C. Steidl, M. G. Klatt, D. A. Scheinberg
The paper identifies tumor-specific MHC ligands in EZH2-mutated DLBCLs by combining epigenetic drugs and interferon gamma, expanding the immunopeptidome for immunotherapy targets.
bioRxiv · Sep 1, 2021 · PreprintImmunology